New directions in the systemic treatment of metastatic thyroid cancer

Michaela J. Higgins, Arlene Forastiere, Shanthi Marur

Research output: Contribution to journalReview articlepeer-review

Abstract

Medical oncologists have traditionally had little to offer patients with metastatic radioactive iodineresistant thyroid cancer. The 3-year survival rate of patients with differentiated thyroid cancer is less than 50%, with little response obtained from standard cytotoxic chemotherapies. In recent years, however, huge advances have been made in understanding the molecular pathways and cellular pathogenesis of this disease. This knowledge has in turn led to the development of a range of targeted therapies, some specific to thyroid cancer genetic alterations such as the RET/PTC translocation, and others that exploit general malignant properties such as angiogenesis. This review highlights novel targeted agents for the treatment of differentiated and medullary thyroid cancers being studied at this time, and the results of recently published trials. We propose that such patients should be managed, whenever possible, within a clinical trial, in order to access the most promising new drugs for thyroid cancer. In cases where trials are unavailable, we recommend off-label use of the currently available oral multikinase inhibitors such as sorafenib and sunitinib rather than traditional chemotherapies.

Original languageEnglish (US)
JournalONCOLOGY
Volume23
Issue number9
StatePublished - Aug 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'New directions in the systemic treatment of metastatic thyroid cancer'. Together they form a unique fingerprint.

Cite this